Eli Lilly plots NDA as second JAK study backs baricitinib for alopecia areata; Alnylam heads to FDA after full vutrisiran data pan out
Eli Lilly has posted positive data from its second Phase III study testing its JAK inhibitor baricitinib in spurring hair regrowth among patients suffering from severe alopecia areata.
Investigators reported a dose-dependent response to the drug, with 35% of the subjects in the 4 mg arm achieving 80% or more scalp hair coverage against 22% in the 2 mg arm. That’s in line with the first Phase III readout.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.